Annual CFF
$17.57 M
+$14.44 M+461.47%
31 December 2023
Summary:
ReShape Lifesciences annual cash flow from financing activities is currently $17.57 million, with the most recent change of +$14.44 million (+461.47%) on 31 December 2023. During the last 3 years, it has risen by +$6.50 million (+58.68%). RSLS annual CFF is now -62.06% below its all-time high of $46.32 million, reached on 31 December 2007.RSLS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
-$24.00 K-100.00%
30 September 2024
Summary:
ReShape Lifesciences quarterly cash flow from financing activities is currently $0.00, with the most recent change of -$24.00 thousand (-100.00%) on 30 September 2024. Over the past year, it has increased by +$338.00 thousand (+100.00%). RSLS quarterly CFF is now -100.00% below its all-time high of $35.33 million, reached on 30 June 2021.RSLS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$5.49 M
+$338.00 K+6.57%
30 September 2024
Summary:
ReShape Lifesciences TTM cash flow from financing activities is currently $5.49 million, with the most recent change of +$338.00 thousand (+6.57%) on 30 September 2024. Over the past year, it has dropped by -$7.27 million (-56.98%). RSLS TTM CFF is now -87.21% below its all-time high of $42.90 million, reached on 30 June 2021.RSLS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +461.5% | +100.0% | -57.0% |
| 3 y3 years | +58.7% | +100.0% | -85.7% |
| 5 y5 years | -47.1% | -100.0% | -85.4% |
RSLS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -47.2% | +461.5% | -100.0% | +100.0% | -85.7% | +1108.3% |
| 5 y | 5 years | -47.2% | +461.5% | -100.0% | +100.0% | -87.2% | +1108.3% |
| alltime | all time | -62.1% | +461.5% | -100.0% | +100.0% | -87.2% | +227.7% |
ReShape Lifesciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $5.49 M(+6.6%) |
| June 2024 | - | $24.00 K(>+9900.0%) | $5.15 M(-30.2%) |
| Mar 2024 | - | $0.00(-100.0%) | $7.37 M(-58.0%) |
| Dec 2023 | $17.57 M(+461.5%) | $5.46 M(-1715.7%) | $17.57 M(+37.8%) |
| Sept 2023 | - | -$338.00 K(-115.0%) | $12.75 M(-2.6%) |
| June 2023 | - | $2.25 M(-77.9%) | $13.09 M(-1.8%) |
| Mar 2023 | - | $10.20 M(+1498.9%) | $13.33 M(+325.9%) |
| Dec 2022 | $3.13 M(-90.6%) | $638.00 K(>+9900.0%) | $3.13 M(+25.6%) |
| Sept 2022 | - | $3000.00(-99.9%) | $2.49 M(-558.1%) |
| June 2022 | - | $2.49 M(>+9900.0%) | -$544.00 K(-101.7%) |
| Mar 2022 | - | $0.00(0.0%) | $32.30 M(-3.0%) |
| Dec 2021 | $33.30 M(+200.7%) | $0.00(-100.0%) | $33.30 M(-13.2%) |
| Sept 2021 | - | -$3.03 M(-108.6%) | $38.37 M(-10.6%) |
| June 2021 | - | $35.33 M(+3433.2%) | $42.90 M(+346.9%) |
| Mar 2021 | - | $1.00 M(-80.3%) | $9.60 M(-13.3%) |
| Dec 2020 | $11.07 M(-18.9%) | $5.07 M(+237.9%) | $11.07 M(+140.3%) |
| Sept 2020 | - | $1.50 M(-26.1%) | $4.61 M(-57.2%) |
| June 2020 | - | $2.03 M(-17.9%) | $10.76 M(-24.0%) |
| Mar 2020 | - | $2.48 M(-277.0%) | $14.15 M(+3.6%) |
| Dec 2019 | $13.66 M(-58.9%) | -$1.40 M(-118.3%) | $13.66 M(-63.6%) |
| Sept 2019 | - | $7.65 M(+41.0%) | $37.54 M(+13.5%) |
| June 2019 | - | $5.43 M(+174.2%) | $33.08 M(-6.0%) |
| Mar 2019 | - | $1.98 M(-91.2%) | $35.18 M(+6.0%) |
| Dec 2018 | $33.20 M(-12.2%) | $22.49 M(+605.8%) | $33.20 M(+209.8%) |
| Sept 2018 | - | $3.19 M(-57.7%) | $10.72 M(-58.0%) |
| June 2018 | - | $7.53 M(>+9900.0%) | $25.51 M(+41.8%) |
| Mar 2018 | - | $0.00(0.0%) | $18.00 M(-52.4%) |
| Dec 2017 | $37.81 M(+135.5%) | $0.00(-100.0%) | $37.81 M(-0.0%) |
| Sept 2017 | - | $17.98 M(>+9900.0%) | $37.81 M(+91.1%) |
| June 2017 | - | $16.20 K(-99.9%) | $19.79 M(-23.1%) |
| Mar 2017 | - | $19.81 M(>+9900.0%) | $25.73 M(+60.3%) |
| Dec 2016 | $16.05 M(-15.3%) | $5000.00(-111.9%) | $16.05 M(-6.0%) |
| Sept 2016 | - | -$42.10 K(-100.7%) | $17.08 M(-44.2%) |
| June 2016 | - | $5.95 M(-41.3%) | $30.62 M(+29.5%) |
| Mar 2016 | - | $10.14 M(+881.4%) | $23.64 M(+24.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | $18.95 M(+143.2%) | $1.03 M(-92.3%) | $18.95 M(+6.7%) |
| Sept 2015 | - | $13.50 M(-1412.8%) | $17.76 M(+443.7%) |
| June 2015 | - | -$1.03 M(-118.9%) | $3.27 M(-49.7%) |
| Mar 2015 | - | $5.45 M(-3509.9%) | $6.50 M(-16.6%) |
| Dec 2014 | $7.79 M(-60.3%) | -$159.90 K(-84.0%) | $7.79 M(-45.2%) |
| Sept 2014 | - | -$997.90 K(-145.3%) | $14.23 M(-19.0%) |
| June 2014 | - | $2.21 M(-67.3%) | $17.56 M(+22.7%) |
| Mar 2014 | - | $6.75 M(+7.5%) | $14.31 M(-27.1%) |
| Dec 2013 | $19.63 M(+27.7%) | $6.27 M(+169.1%) | $19.63 M(+40.6%) |
| Sept 2013 | - | $2.33 M(-324.4%) | $13.96 M(-11.5%) |
| June 2013 | - | -$1.04 M(-108.6%) | $15.77 M(-43.7%) |
| Mar 2013 | - | $12.06 M(+1898.6%) | $27.99 M(+82.0%) |
| Dec 2012 | $15.38 M(+22.9%) | $603.60 K(-85.4%) | $15.38 M(+7.9%) |
| Sept 2012 | - | $4.14 M(-63.0%) | $14.25 M(-39.5%) |
| June 2012 | - | $11.18 M(-2132.1%) | $23.55 M(+90.3%) |
| Mar 2012 | - | -$550.40 K(+4.9%) | $12.38 M(-1.1%) |
| Dec 2011 | $12.52 M(-65.6%) | -$524.80 K(-103.9%) | $12.52 M(-69.8%) |
| Sept 2011 | - | $13.44 M(>+9900.0%) | $41.39 M(+24.0%) |
| June 2011 | - | $13.10 K(-103.2%) | $33.39 M(+3.0%) |
| Mar 2011 | - | -$412.90 K(-101.5%) | $32.41 M(-11.0%) |
| Dec 2010 | $36.42 M(+176.3%) | $28.35 M(+421.3%) | $36.42 M(+1158.3%) |
| Sept 2010 | - | $5.44 M(-664.7%) | $2.89 M(-167.4%) |
| June 2010 | - | -$963.10 K(-126.8%) | -$4.30 M(-364.5%) |
| Mar 2010 | - | $3.59 M(-169.4%) | $1.62 M(-87.7%) |
| Dec 2009 | $13.18 M(+317.0%) | -$5.17 M(+195.3%) | $13.18 M(-48.4%) |
| Sept 2009 | - | -$1.75 M(-135.3%) | $25.55 M(-1.4%) |
| June 2009 | - | $4.96 M(-67.3%) | $25.93 M(+31.5%) |
| Mar 2009 | - | $15.15 M(+110.5%) | $19.71 M(+523.7%) |
| Dec 2008 | $3.16 M(-93.2%) | $7.20 M(-622.9%) | $3.16 M(-178.3%) |
| Sept 2008 | - | -$1.38 M(+9.4%) | -$4.04 M(+51.7%) |
| June 2008 | - | -$1.26 M(-10.3%) | -$2.66 M(+89.7%) |
| Mar 2008 | - | -$1.40 M | -$1.40 M |
| Dec 2007 | $46.32 M(+13.7%) | - | - |
| Dec 2006 | $40.72 M(+152.7%) | - | - |
| Dec 2005 | $16.11 M | - | - |
FAQ
- What is ReShape Lifesciences annual cash flow from financing activities?
- What is the all time high annual CFF for ReShape Lifesciences?
- What is ReShape Lifesciences annual CFF year-on-year change?
- What is ReShape Lifesciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly CFF year-on-year change?
- What is ReShape Lifesciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for ReShape Lifesciences?
- What is ReShape Lifesciences TTM CFF year-on-year change?
What is ReShape Lifesciences annual cash flow from financing activities?
The current annual CFF of RSLS is $17.57 M
What is the all time high annual CFF for ReShape Lifesciences?
ReShape Lifesciences all-time high annual cash flow from financing activities is $46.32 M
What is ReShape Lifesciences annual CFF year-on-year change?
Over the past year, RSLS annual cash flow from financing activities has changed by +$14.44 M (+461.47%)
What is ReShape Lifesciences quarterly cash flow from financing activities?
The current quarterly CFF of RSLS is $0.00
What is the all time high quarterly CFF for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly cash flow from financing activities is $35.33 M
What is ReShape Lifesciences quarterly CFF year-on-year change?
Over the past year, RSLS quarterly cash flow from financing activities has changed by +$338.00 K (+100.00%)
What is ReShape Lifesciences TTM cash flow from financing activities?
The current TTM CFF of RSLS is $5.49 M
What is the all time high TTM CFF for ReShape Lifesciences?
ReShape Lifesciences all-time high TTM cash flow from financing activities is $42.90 M
What is ReShape Lifesciences TTM CFF year-on-year change?
Over the past year, RSLS TTM cash flow from financing activities has changed by -$7.27 M (-56.98%)